57
Views
23
CrossRef citations to date
0
Altmetric
Case Series

Successful treatment with apatinib for refractory recurrent malignant gliomas: a case series

, , &
Pages 837-845 | Published online: 14 Feb 2017

References

  • OmuroADeAngelisLMGlioblastoma and other malignant gliomas: a clinical reviewJAMA2013310171842185024193082
  • JohnsonBEMazorTHongCMutational analysis reveals the origin and therapy-driven evolution of recurrent gliomaScience2014343618919324336570
  • NiederCGrosuAMollsMA comparison of treatment results for recurrent malignant gliomasCancer Treat Rev200026639740911139371
  • HuncharekMMuscatJTreatment of recurrent high grade astrocytoma; results of a systematic review of 1,415 patientsAnticancer Res1997182B13031311
  • LiJQinSXuJApatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trialJ Clin Oncol201331263219322523918952
  • LiJQinSXuJRandomized, double-blind, placebo-controlled phase III trial of apatinib in patients with chemotherapy-refractory advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junctionJ Clin Oncol201634131448145426884585
  • ZhangLShiMHuangCA phase II, multicenter, placebo-controlled trial of apatinib in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after two previous treatment regimensJ Clin Oncol20123015_suppl7548
  • HuXZhangJXuBMulticenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancerInt J Cancer201413581961196924604288
  • HuXCaoJHuWMulticenter phase II study of apatinib in non-triple-negative metastatic breast cancerBMC Cancer20141411824383403
  • QinSApatinib in Chinese patients with advanced hepatocellular carcinoma: a phase II randomized, open-label trialAsco Meeting Abstracts20143215_suppl4019
  • DützmannSGeßlerFBinkARisk of ischemia in glioma surgery: comparison of first and repeat proceduresJ Neurooncol2012107359960722249690
  • GalldiksNBerhornTBlauTDunklVFinkGRSchroeterM“One week on–one week off”: efficacy and side effects of dose-intensified temozolomide chemotherapy: experiences of a single centerJ Neurooncol2013112220921523299464
  • ReardonDADesjardinsAVredenburghJJMetronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II studyBr J Cancer2009101121986199419920819
  • FriedmanHSPradosMDWenPYBevacizumab alone and in combination with irinotecan in recurrent glioblastomaJ Clin Oncol200927284733474019720927
  • YangQYGuoCCChenZPProfile of nimotuzumab in the treatment of high-grade gliomaOnco Targets Ther2015881982525926743
  • EpelmanSOdoneVGorenderEMedeirosRSSMartinsLPhase II study of nimotuzumab and radiotherapy in children and adolescents with newly diagnosed diffuse intrinsic pontine gliomas (DIPG)J Clin Oncol20153315_suppl10061
  • LiJZhaoXChenLSafety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignanciesBMC Cancer201010152953620923544
  • CoweyCLSonpavdeGHutsonTENew advancements and developments in treatment of renal cell carcinoma: focus on pazopanibOnco Targets Ther200934147155